Dr. Senthilkumar Damodaran, M.D. PH.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 115
Licensed in Texas since 2015, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license Q5786 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Physicians Referral Service (2,765 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 115
- Services billed
- 307
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 49 |
| Established patient office or other outpatient visit, 30-39 minutes | 104 | 59 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Houston, TX | 198 |
| Anastrozole Other prescribers in Houston, TX | 51 |
| Verzenio (abemaciclib) | 39 |
| Ondansetron Hcl Other prescribers in Houston, TX | 27 |
| Ibrance (palbociclib) | 24 |
| Exemestane | 16 |
| Prochlorperazine Maleate Other prescribers in Houston, TX | 16 |
| Kisqali (ribociclib succinate) | 16 |
| Everolimus | 14 |
| Tamoxifen Citrate Other prescribers in Houston, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 16 payments worth $11,511 in total to this clinician.
| Eli Lilly and Company | $5,983 |
|---|---|
| AstraZeneca UK Limited | $5,528 |
| Consulting Fee | $9,128 |
|---|---|
| Travel and Lodging | $2,210 |
| Food and Beverage | $173 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Mar 12, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $3,853 |
| Eli Lilly and Company May 12, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $2,400 |
| AstraZeneca UK Limited Jul 29, 2025 | Consulting Fee | $1,675 |
| Eli Lilly and Company Sep 25, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,200 |
| Eli Lilly and Company Apr 28, 2025 | Travel and Lodging travel to NEW YORK CITY, TX · in-kind | $958 |
| Eli Lilly and Company Apr 28, 2025 | Travel and Lodging travel to NEW YORK CITY, NY · in-kind | $347 |
| Eli Lilly and Company Apr 28, 2025 | Travel and Lodging travel to NEW YORK CITY, NY · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $278 |
| Eli Lilly and Company Apr 28, 2025 | Travel and Lodging travel to NEW YORK CITY, NY · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $274 |
| Eli Lilly and Company Apr 28, 2025 | Travel and Lodging travel to NEW YORK CITY, NY · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $257 |
| Eli Lilly and Company May 16, 2025 | Travel and Lodging travel to NEW YORK, NY Company’s descriptionTRAVEL EXPENSES RELATED TO PROVIDING RESEARCH RELATED SERVICES | $95.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $2,711,423 in research payments for these studies, mostly to the institutions running them.
- Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
Daiichi Sankyo Inc. · Active, not recruiting · NCT05633979 - A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
AstraZeneca Pharmaceuticals LP - A Phase I/II, open label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth re…
Novartis Pharmaceuticals Corporation - A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in combination with ribocilcib and fulvestrant in subjects participants withER-positive, HER2- negative and GRPR-positive breast cancer, ex…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.